[FG] Kappos Ludwig
Publications
1,260 found
Show per page
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum’, Neurology Clinical Practice, 15(4). Available at: https://doi.org/10.1212/cpj.0000000000200499.
Einsiedler, Maximilian et al. (2025) ‘Treatment Strategies and Disease Activity During Pregnancy and Postpartum’, Neurology Clinical Practice, 15(4). Available at: https://doi.org/10.1212/cpj.0000000000200499.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13185-y.
Burguet Villena, Federico et al. (2025) ‘Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-025-13185-y.
Montobbio, Noemi et al. (2025) ‘Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials’, Ebiomedicine, 117. Available at: https://doi.org/10.1016/j.ebiom.2025.105802.
Montobbio, Noemi et al. (2025) ‘Uncovering a bias in estimated treatment effects on PIRA in multiple sclerosis clinical trials’, Ebiomedicine, 117. Available at: https://doi.org/10.1016/j.ebiom.2025.105802.
Bovis, Francesca et al. (2025) ‘Personalized Treatment Response in Progressive MS: Can the Patient’s Profile Influence the Outcome?’, Brain and Behavior, 15. Available at: https://doi.org/10.1002/brb3.70459.
Bovis, Francesca et al. (2025) ‘Personalized Treatment Response in Progressive MS: Can the Patient’s Profile Influence the Outcome?’, Brain and Behavior, 15. Available at: https://doi.org/10.1002/brb3.70459.
Harris, Sarah et al. (2025) ‘Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70222.
Harris, Sarah et al. (2025) ‘Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials’, European Journal of Neurology, 32. Available at: https://doi.org/10.1111/ene.70222.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Müller, Jannis et al. (2025) ‘Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis’, JAMA Neurology. 14.04.2025, 82(6), pp. 614–625. Available at: https://doi.org/10.1001/jamaneurol.2025.0495.
Wali, Nabila et al. (2025) ‘Endovascular treatment in patients with acute ischemic stroke presenting beyond 6 h after symptom onset: An international multicenter cohort study of the EVA-TRISP collaboration’, European Stroke Journal, 10(2), pp. 422–430. Available at: https://doi.org/10.1177/23969873241277437.
Wali, Nabila et al. (2025) ‘Endovascular treatment in patients with acute ischemic stroke presenting beyond 6 h after symptom onset: An international multicenter cohort study of the EVA-TRISP collaboration’, European Stroke Journal, 10(2), pp. 422–430. Available at: https://doi.org/10.1177/23969873241277437.
Martina, Greselin et al. (2025) ‘AI-assisted identification of disability patterns within identical EDSS grades’, Mult Scler ., 31(6), pp. 677–688. Available at: https://doi.org/10.1177/13524585251327300.
Martina, Greselin et al. (2025) ‘AI-assisted identification of disability patterns within identical EDSS grades’, Mult Scler ., 31(6), pp. 677–688. Available at: https://doi.org/10.1177/13524585251327300.
Kappos, Ludwig et al. (2025) ‘Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials’, Neurology, 104(10). Available at: https://doi.org/10.1212/WNL.0000000000213558.
Kappos, Ludwig et al. (2025) ‘Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials’, Neurology, 104(10). Available at: https://doi.org/10.1212/WNL.0000000000213558.
Géraldine, Androdias et al. (2025) ‘De-escalating and discontinuing disease-modifying therapies in multiple sclerosis’, Brain, 148(5), pp. 1459–1478. Available at: https://doi.org/10.1093/brain/awae409.
Géraldine, Androdias et al. (2025) ‘De-escalating and discontinuing disease-modifying therapies in multiple sclerosis’, Brain, 148(5), pp. 1459–1478. Available at: https://doi.org/10.1093/brain/awae409.
Özgür, Yaldizli et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251335466 .
Özgür, Yaldizli et al. (2025) ‘Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251335466 .
Mario, Ocampo-Pineda et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurol Neuroimmunol Neuroinflamm . , 12(3), p. e200388. Available at: https://doi.org/10.1212/NXI.0000000000200388.
Mario, Ocampo-Pineda et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurol Neuroimmunol Neuroinflamm . , 12(3), p. e200388. Available at: https://doi.org/10.1212/NXI.0000000000200388.
Ocampo-Pineda, Mario et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurology: Neuroimmunology and NeuroInflammation, 12(3). Available at: https://doi.org/10.1212/NXI.0000000000200388.
Ocampo-Pineda, Mario et al. (2025) ‘White Matter Tract Degeneration in Multiple Sclerosis Patients With Progression Independent of Relapse Activity’, Neurology: Neuroimmunology and NeuroInflammation, 12(3). Available at: https://doi.org/10.1212/NXI.0000000000200388.
Riccardo, Galbusera et al. (2025) ‘Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study’, Brain Pathol ., p. e70010. Available at: https://doi.org/10.1111/bpa.70010.
Riccardo, Galbusera et al. (2025) ‘Quantitative T1 is sensitive to cortical remyelination in multiple sclerosis: A postmortem MRI study’, Brain Pathol ., p. e70010. Available at: https://doi.org/10.1111/bpa.70010.
Mallucci, Giulia et al. (2025) ‘Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis’, Multiple Sclerosis Journal, 31(4), pp. 497–501. Available at: https://doi.org/10.1177/13524585241305966.
Mallucci, Giulia et al. (2025) ‘Neurostatus-SMARTCARE clinical trial: Enabling health care professionals to assess EDSS for decentralized trials in multiple sclerosis’, Multiple Sclerosis Journal, 31(4), pp. 497–501. Available at: https://doi.org/10.1177/13524585241305966.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Müller, Jannis et al. (2025) ‘Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study’, CNS Drugs, 39(4), pp. 403–416. Available at: https://doi.org/10.1007/s40263-025-01164-w.
Brunner, Eveline et al. (2025) ‘Atherosclerosis in patients with cervical artery dissection’, European Stroke Journal, 10(1), pp. 198–205. Available at: https://doi.org/10.1177/23969873241274547.
Brunner, Eveline et al. (2025) ‘Atherosclerosis in patients with cervical artery dissection’, European Stroke Journal, 10(1), pp. 198–205. Available at: https://doi.org/10.1177/23969873241274547.
Giulio, Disanto et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Mult Scler J Exp Transl Clin ., 11(1), p. 20552173251315457. Available at: https://doi.org/10.1177/20552173251315457.
Giulio, Disanto et al. (2025) ‘Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS Cohort’, Mult Scler J Exp Transl Clin ., 11(1), p. 20552173251315457. Available at: https://doi.org/10.1177/20552173251315457.
Ralph, Hb Benedict et al. (2025) ‘Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials’, Mult Scler Relat Disord . [Preprint]. Available at: https://doi.org/10.1016/j.msard.2025.106310.
Ralph, Hb Benedict et al. (2025) ‘Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials’, Mult Scler Relat Disord . [Preprint]. Available at: https://doi.org/10.1016/j.msard.2025.106310.
Pless, Silvan et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-024-12818-y.
Pless, Silvan et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, Journal of Neurology, 272. Available at: https://doi.org/10.1007/s00415-024-12818-y.
Paolo A, Muraro et al. (2025) ‘Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT’, Nat Rev Neurol . , 21(3), pp. 140–158. Available at: https://doi.org/10.1038/s41582-024-01050-x.
Paolo A, Muraro et al. (2025) ‘Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT’, Nat Rev Neurol . , 21(3), pp. 140–158. Available at: https://doi.org/10.1038/s41582-024-01050-x.
Silvan, Pless et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, J Neurol . , 272(2), p. 119. Available at: https://doi.org/doi: 10.1007/s00415-024-12818-y.
Silvan, Pless et al. (2025) ‘CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis’, J Neurol . , 272(2), p. 119. Available at: https://doi.org/doi: 10.1007/s00415-024-12818-y.
Patrick, Vermersch et al. (2025) ‘Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy’, Mult Scler Relat Disord . , 94, p. 106259. Available at: https://doi.org/10.1016/j.msard.2025.106259.
Patrick, Vermersch et al. (2025) ‘Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy’, Mult Scler Relat Disord . , 94, p. 106259. Available at: https://doi.org/10.1016/j.msard.2025.106259.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Oechtering, Johanna et al. (2025) ‘Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 12(2). Available at: https://doi.org/10.1212/nxi.0000000000200361.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Benkert, Pascal et al. (2025) ‘Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 104–115. Available at: https://doi.org/10.1002/ana.27096.
Damiano, Marastoni et al. (2025) ‘Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis’, Neurol Neuroimmunol Neuroinflamm . 01.05.2025, 12(4), p. e200399. Available at: https://doi.org/10.1212/NXI.0000000000200399.
Damiano, Marastoni et al. (2025) ‘Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis’, Neurol Neuroimmunol Neuroinflamm . 01.05.2025, 12(4), p. e200399. Available at: https://doi.org/10.1212/NXI.0000000000200399.
Douglas L, Arnold et al. (2025) ‘Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251325086.
Douglas L, Arnold et al. (2025) ‘Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS’, Mult Scler . [Preprint]. Available at: https://doi.org/10.1177/13524585251325086.
Müller, Jannis, Derfuss, Tobias and Yaldizli, Özgür (2025) ‘Klinische Grundlagen der MS’, in Multiple Sklerose verstehen und behandeln. Springer (Multiple Sklerose verstehen und behandeln).
Müller, Jannis, Derfuss, Tobias and Yaldizli, Özgür (2025) ‘Klinische Grundlagen der MS’, in Multiple Sklerose verstehen und behandeln. Springer (Multiple Sklerose verstehen und behandeln).
Pontillo, G. et al. (2025) ‘More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis’, Human Brain Mapping, 46(1). Available at: https://doi.org/10.1002/hbm.70107.
Pontillo, G. et al. (2025) ‘More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis’, Human Brain Mapping, 46(1). Available at: https://doi.org/10.1002/hbm.70107.
Sanabria-Diaz, Gretel et al. (2025) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 134–148. Available at: https://doi.org/10.1002/ana.27102.
Sanabria-Diaz, Gretel et al. (2025) ‘Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis’, Annals of Neurology, 97(1), pp. 134–148. Available at: https://doi.org/10.1002/ana.27102.
Sharmin, Sifat et al. (2025) ‘MSoutcomes: CORe Multiple Sclerosis Outcomes Toolkit’. Available at: https://doi.org/https://CRAN.R-project.org/package=MSoutcomes.
Sharmin, Sifat et al. (2025) ‘MSoutcomes: CORe Multiple Sclerosis Outcomes Toolkit’. Available at: https://doi.org/https://CRAN.R-project.org/package=MSoutcomes.
Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology: Neuroimmunology and NeuroInflammation, 12(1). Available at: https://doi.org/10.1212/NXI.0000000000200347.
Gomes, Ana Beatriz Ayroza Galvão Ribeiro et al. (2024) ‘Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease’, Neurology: Neuroimmunology and NeuroInflammation, 12(1). Available at: https://doi.org/10.1212/NXI.0000000000200347.
Barakovic, Muhamed et al. (2024) ‘A novel imaging marker of cortical “cellularity” in multiple sclerosis patients’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-60497-6.
Barakovic, Muhamed et al. (2024) ‘A novel imaging marker of cortical “cellularity” in multiple sclerosis patients’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-60497-6.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials, 25(1). Available at: https://doi.org/10.1186/s13063-024-08454-6.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial’, Trials, 25(1). Available at: https://doi.org/10.1186/s13063-024-08454-6.
Oh, J. et al. (2024) ‘Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-023-49299-4.
Oh, J. et al. (2024) ‘Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-023-49299-4.
Zietz, Annaelle et al. (2024) ‘Enhancement of STroke REhabilitation with Levodopa (ESTREL): Rationale and design of a randomized placebo-controlled, double blind superiority trial’, European Stroke Journal, 9(4), pp. 1093–1102. Available at: https://doi.org/10.1177/23969873241255867.
Zietz, Annaelle et al. (2024) ‘Enhancement of STroke REhabilitation with Levodopa (ESTREL): Rationale and design of a randomized placebo-controlled, double blind superiority trial’, European Stroke Journal, 9(4), pp. 1093–1102. Available at: https://doi.org/10.1177/23969873241255867.
Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103(10). Available at: https://doi.org/10.1212/WNL.0000000000209976.
Pontillo, Giuseppe et al. (2024) ‘Disentangling Neurodegeneration From Aging in Multiple Sclerosis Using Deep Learning: The Brain-Predicted Disease Duration Gap’, Neurology, 103(10). Available at: https://doi.org/10.1212/WNL.0000000000209976.
Woelfle, Tim et al. (2024) ‘Benchmarking Human–AI collaboration for common evidence appraisal tools’, Journal of Clinical Epidemiology. 12.09.2024, 175. Available at: https://doi.org/10.1016/j.jclinepi.2024.111533.
Woelfle, Tim et al. (2024) ‘Benchmarking Human–AI collaboration for common evidence appraisal tools’, Journal of Clinical Epidemiology. 12.09.2024, 175. Available at: https://doi.org/10.1016/j.jclinepi.2024.111533.
Geraldes, R. et al. (2024) ‘The influence of MOGAD on diagnosis of multiple sclerosis using MRI’, Nature Reviews Neurology, 20(10), pp. 620–635. Available at: https://doi.org/10.1038/s41582-024-01005-2.
Geraldes, R. et al. (2024) ‘The influence of MOGAD on diagnosis of multiple sclerosis using MRI’, Nature Reviews Neurology, 20(10), pp. 620–635. Available at: https://doi.org/10.1038/s41582-024-01005-2.
Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology. 30.08.2024, 103(6). Available at: https://doi.org/10.1212/WNL.0000000000209604.
Müller, Jannis et al. (2024) ‘Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions’, Neurology. 30.08.2024, 103(6). Available at: https://doi.org/10.1212/WNL.0000000000209604.
Cagol, Alessandro et al. (2024) ‘Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(6). Available at: https://doi.org/10.1212/NXI.0000000000200299.
Cagol, Alessandro et al. (2024) ‘Advanced Quantitative MRI Unveils Microstructural Thalamic Changes Reflecting Disease Progression in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(6). Available at: https://doi.org/10.1212/NXI.0000000000200299.
Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.
Cortese, Rosa et al. (2024) ‘Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis’, Annals of Neurology, 96(2), pp. 276–288. Available at: https://doi.org/10.1002/ana.26951.
Greselin, Martina et al. (2024) ‘Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort’, Bioengineering, 11(8), p. 858. Available at: https://doi.org/10.3390/bioengineering11080858.
Greselin, Martina et al. (2024) ‘Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort’, Bioengineering, 11(8), p. 858. Available at: https://doi.org/10.3390/bioengineering11080858.
Sastre-Garriga, J. et al. (2024) ‘Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives’, Neurology, 103(3). Available at: https://doi.org/10.1212/wnl.0000000000209677.
Sastre-Garriga, J. et al. (2024) ‘Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives’, Neurology, 103(3). Available at: https://doi.org/10.1212/wnl.0000000000209677.
Kappos, L. et al. (2024) ‘Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial’, Journal of Neurology, 271(7), pp. 4599–4609. Available at: https://doi.org/10.1007/s00415-024-12417-x.
Kappos, L. et al. (2024) ‘Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial’, Journal of Neurology, 271(7), pp. 4599–4609. Available at: https://doi.org/10.1007/s00415-024-12417-x.
Ciccarelli, O. et al. (2024) ‘Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis’, Neurology, 103(1). Available at: https://doi.org/10.1212/WNL.0000000000209444.
Ciccarelli, O. et al. (2024) ‘Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis’, Neurology, 103(1). Available at: https://doi.org/10.1212/WNL.0000000000209444.
Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology. 13.05.2024, 81(6), pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.
Kaufmann, Josefin E. et al. (2024) ‘Antithrombotic Treatment for Cervical Artery Dissection: A Systematic Review and Individual Patient Data Meta-Analysis’, JAMA Neurology. 13.05.2024, 81(6), pp. 630–637. Available at: https://doi.org/10.1001/jamaneurol.2024.1141.
Chitnis, T. et al. (2024) ‘Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS’, Multiple Sclerosis Journal, 30(7), pp. 833–842. Available at: https://doi.org/10.1177/13524585241242050.
Chitnis, T. et al. (2024) ‘Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS’, Multiple Sclerosis Journal, 30(7), pp. 833–842. Available at: https://doi.org/10.1177/13524585241242050.
Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.
Diem, L et al. (2024) ‘Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers’, Multiple Sclerosis and Related Disorders, 86. Available at: https://doi.org/10.1016/j.msard.2024.105570.
Hirt, Julian et al. (2024) ‘Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis’, Journal of Neurology, 271(6), pp. 3131–3141. Available at: https://doi.org/10.1007/s00415-024-12366-5.
Hirt, Julian et al. (2024) ‘Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis’, Journal of Neurology, 271(6), pp. 3131–3141. Available at: https://doi.org/10.1007/s00415-024-12366-5.
Wendebourg, Maria Janina et al. (2024) ‘Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis’, European Journal of Neurology, 31(6). Available at: https://doi.org/10.1111/ene.16268.
Wendebourg, Maria Janina et al. (2024) ‘Cervical and thoracic spinal cord gray matter atrophy is associated with disability in patients with amyotrophic lateral sclerosis’, European Journal of Neurology, 31(6). Available at: https://doi.org/10.1111/ene.16268.
Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology. 16.02.2024, 95(5), pp. 886–897. Available at: https://doi.org/10.1002/ana.26886.
Kaufmann, Josefin E. et al. (2024) ‘Toward Individual Treatment in Cervical Artery Dissection: Subgroup Analysis of the TREAT-CAD Randomized Trial’, Annals of Neurology. 16.02.2024, 95(5), pp. 886–897. Available at: https://doi.org/10.1002/ana.26886.
Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.
Khalil, Michael et al. (2024) ‘Neurofilaments as biomarkers in neurological disorders — towards clinical application’, Nature Reviews Neurology, 20(5), pp. 269–287. Available at: https://doi.org/10.1038/s41582-024-00955-x.
Papadopoulou, Athina et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology. 20.02.2024, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.
Papadopoulou, Athina et al. (2024) ‘Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus’, Clinical Neurophysiology. 20.02.2024, 161, pp. 122–132. Available at: https://doi.org/10.1016/j.clinph.2024.02.020.
Fox, R.J. et al. (2024) ‘Temporal Relationship between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients with Multiple Sclerosis’, Neurology, 102(9). Available at: https://doi.org/10.1212/WNL.0000000000209357.
Fox, R.J. et al. (2024) ‘Temporal Relationship between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients with Multiple Sclerosis’, Neurology, 102(9). Available at: https://doi.org/10.1212/WNL.0000000000209357.
Woelfle, Tim et al. (2024) ‘Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.04.21.24306137.
Woelfle, Tim et al. (2024) ‘Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.04.21.24306137.
Weigel, M. et al. (2024) ‘Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.04.18.589707.
Weigel, M. et al. (2024) ‘Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.04.18.589707.
Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.
Hirt, Julian et al. (2024) ‘Use of pragmatic randomized trials in multiple sclerosis: A systematic overview’, Multiple Sclerosis Journal, 30(4-5), pp. 463–478. Available at: https://doi.org/10.1177/13524585231221938.
Lazzarotto, A. et al. (2024) ‘Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis’, Brain, 147(4), pp. 1331–1343. Available at: https://doi.org/10.1093/brain/awae024.
Lazzarotto, A. et al. (2024) ‘Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis’, Brain, 147(4), pp. 1331–1343. Available at: https://doi.org/10.1093/brain/awae024.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.03.22.24304720.
Janiaud, Perrine et al. (2024) ‘MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial’, medRxiv [Preprint]. Cold Spring Harbor Laboratory (medRxiv). Available at: https://doi.org/10.1101/2024.03.22.24304720.
Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147(3), pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.
Callegari, Ilaria et al. (2024) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’, Brain, 147(3), pp. 839–848. Available at: https://doi.org/10.1093/brain/awad424.
Gloor M et al. (2024) ‘Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging’, European Radiology. 02.09.2023, 34(3), pp. 1680–1691. Available at: https://doi.org/10.1007/s00330-023-10173-6.
Gloor M et al. (2024) ‘Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging’, European Radiology. 02.09.2023, 34(3), pp. 1680–1691. Available at: https://doi.org/10.1007/s00330-023-10173-6.
Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/NXI.0000000000200212.
Oechtering, Johanna et al. (2024) ‘Complement Activation Is Associated With Disease Severity in Multiple Sclerosis’, Neurology: Neuroimmunology and NeuroInflammation, 11(2). Available at: https://doi.org/10.1212/NXI.0000000000200212.
Cagol, Alessandro et al. (2024) ‘Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis’, JAMA Neurology, 81(2), pp. 143–153. Available at: https://doi.org/10.1001/jamaneurol.2023.4737.
Cagol, Alessandro et al. (2024) ‘Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis’, JAMA Neurology, 81(2), pp. 143–153. Available at: https://doi.org/10.1001/jamaneurol.2023.4737.
Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271(2), pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.
Kappos, Ludwig et al. (2024) ‘Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension’, Journal of Neurology, 271(2), pp. 642–657. Available at: https://doi.org/10.1007/s00415-023-11943-4.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/WNL.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/WNL.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Cagol, Alessandro et al. (2024) ‘Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS’, Neurology, 102(1). Available at: https://doi.org/10.1212/wnl.0000000000207768.
Wilson, David et al. (2024) ‘Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury’, Clinical Chemistry and Laboratory Medicine, 62(2), pp. 322–331. Available at: https://doi.org/10.1515/cclm-2023-0518.
Wilson, David et al. (2024) ‘Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury’, Clinical Chemistry and Laboratory Medicine, 62(2), pp. 322–331. Available at: https://doi.org/10.1515/cclm-2023-0518.
Derfuss, T. et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.
Derfuss, T. et al. (2024) ‘Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials’, Therapeutic Advances in Neurological Disorders, 17. Available at: https://doi.org/10.1177/17562864241277736.
Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology , 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.
Filioglo, Andrei et al. (2024) ‘Corrigendum: Tandem occlusions involving the internal carotid and anterior cerebral arteries—A rare form of stroke: results from the multicenter EVATRISP collaboration study (Frontiers in Neurology, (2022), 13, (1024891), 10.3389/fneur.2022.1024891)’, Frontiers in Neurology , 15. Available at: https://doi.org/10.3389/fneur.2024.1450372.
Lorscheider, Johannes et al. (2024) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network’, Journal of Neurology, Neurosurgery and Psychiatry, pp. jnnp–2024–334700. Available at: https://doi.org/10.1136/jnnp-2024-334700.
Lorscheider, Johannes et al. (2024) ‘Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network’, Journal of Neurology, Neurosurgery and Psychiatry, pp. jnnp–2024–334700. Available at: https://doi.org/10.1136/jnnp-2024-334700.
Nybondas, Miranda et al. (2024) ‘Intravenous thrombolysis in young adults with ischemic stroke: A cohort study from the international TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241304305.
Nybondas, Miranda et al. (2024) ‘Intravenous thrombolysis in young adults with ischemic stroke: A cohort study from the international TRISP collaboration’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241304305.
Riegler, Christoph et al. (2024) ‘Endovascular therapy in patients with acute intracranial non-terminal internal carotid artery occlusion (ICA-I)’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241278948.
Riegler, Christoph et al. (2024) ‘Endovascular therapy in patients with acute intracranial non-terminal internal carotid artery occlusion (ICA-I)’, European Stroke Journal [Preprint]. Available at: https://doi.org/10.1177/23969873241278948.
Steinegger, L. et al. (2024) ‘Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1451693.
Steinegger, L. et al. (2024) ‘Acute leukoencephalopathy associated with daratumumab treatment in POEMS syndrome: a case report’, Frontiers in Immunology, 15. Available at: https://doi.org/10.3389/fimmu.2024.1451693.
Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.
Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.
Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.
Abdelhak, Ahmed et al. (2023) ‘Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis’, JAMA Neurology, 80(12), pp. 1317–1325. Available at: https://doi.org/10.1001/jamaneurol.2023.3997.
Baumgartner P et al. (2023) ‘Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study’, European Stroke Journal, 8(4), pp. 966–973. Available at: https://doi.org/10.1177/23969873231185895.
Baumgartner P et al. (2023) ‘Safety and effectiveness of IV Thrombolysis in retinal artery occlusion: A multicenter retrospective cohort study’, European Stroke Journal, 8(4), pp. 966–973. Available at: https://doi.org/10.1177/23969873231185895.
Diouf I et al. (2023) ‘Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial’, Journal of Neurology, Neurosurgery and Psychiatry, 94(12), pp. 1004–1011. Available at: https://doi.org/10.1136/jnnp-2023-331499.
Diouf I et al. (2023) ‘Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: Causal inference to emulate a multiarm randomised trial’, Journal of Neurology, Neurosurgery and Psychiatry, 94(12), pp. 1004–1011. Available at: https://doi.org/10.1136/jnnp-2023-331499.
Hauser, S.L. et al. (2023) ‘Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis’, in Multiple Sclerosis and Related Disorders. Elsevier B.V. (Multiple Sclerosis and Related Disorders). Available at: https://doi.org/10.1016/j.msard.2023.105308.
Hauser, S.L. et al. (2023) ‘Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis’, in Multiple Sclerosis and Related Disorders. Elsevier B.V. (Multiple Sclerosis and Related Disorders). Available at: https://doi.org/10.1016/j.msard.2023.105308.
Montalban, X. et al. (2023) ‘Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)’. Elsevier B.V., 80. Available at: https://doi.org/10.1016/j.msard.2023.105328.
Montalban, X. et al. (2023) ‘Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)’. Elsevier B.V., 80. Available at: https://doi.org/10.1016/j.msard.2023.105328.
Woelfle, Tim et al. (2023) ‘Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105104.
Woelfle, Tim et al. (2023) ‘Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity’, Multiple Sclerosis and Related Disorders, 80. Available at: https://doi.org/10.1016/j.msard.2023.105104.
Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology. 02.10.2023, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.
Müller, Jannis et al. (2023) ‘Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review’, JAMA Neurology. 02.10.2023, 80(11), pp. 1232–1245. Available at: https://doi.org/10.1001/jamaneurol.2023.3331.
Callegari, I. et al. (2023) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560121.
Callegari, I. et al. (2023) ‘Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560121.
Hauser S.L. et al. (2023) ‘The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment’, Neurology and Therapy, 12(5), pp. 1491–1515. Available at: https://doi.org/10.1007/s40120-023-00518-0.
Hauser S.L. et al. (2023) ‘The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment’, Neurology and Therapy, 12(5), pp. 1491–1515. Available at: https://doi.org/10.1007/s40120-023-00518-0.
Seystahl K et al. (2023) ‘IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors’, Neurology, 101(12), pp. E1241–E1255. Available at: https://doi.org/10.1212/WNL.0000000000207624.
Seystahl K et al. (2023) ‘IV Thrombolysis With or Without Endovascular Treatment for Suspected Ischemic Stroke in Patients With Intracranial Tumors’, Neurology, 101(12), pp. E1241–E1255. Available at: https://doi.org/10.1212/WNL.0000000000207624.
Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94(9), pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.
Harding-Forrester, Sam et al. (2023) ‘Disability accrual in primary and secondary progressive multiple sclerosis’, Journal of Neurology, Neurosurgery and Psychiatry, 94(9), pp. 707–717. Available at: https://doi.org/10.1136/jnnp-2022-330726.
Todea, Alexandra Ramona et al. (2023) ‘A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients’, Journal of Magnetic Resonance Imaging, 58(3), pp. 864–876. Available at: https://doi.org/10.1002/jmri.28618.
Todea, Alexandra Ramona et al. (2023) ‘A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients’, Journal of Magnetic Resonance Imaging, 58(3), pp. 864–876. Available at: https://doi.org/10.1002/jmri.28618.
Altersberger, Valerian L. et al. (2023) ‘Intravenous Thrombolysis 4.5–9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration’, Annals of Neurology. 28.04.2023, 94(2), pp. 309–320. Available at: https://doi.org/10.1002/ana.26669.
Altersberger, Valerian L. et al. (2023) ‘Intravenous Thrombolysis 4.5–9 Hours After Stroke Onset: A Cohort Study from the TRISP Collaboration’, Annals of Neurology. 28.04.2023, 94(2), pp. 309–320. Available at: https://doi.org/10.1002/ana.26669.
Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.
Bar-Or, Amit et al. (2023) ‘Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials’, eBioMedicine, 93. Available at: https://doi.org/10.1016/j.ebiom.2023.104662.
Pless S et al. (2023) ‘Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study’, Journal of Neurology, 270(7), pp. 3451–3463. Available at: https://doi.org/10.1007/s00415-023-11671-9.
Pless S et al. (2023) ‘Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study’, Journal of Neurology, 270(7), pp. 3451–3463. Available at: https://doi.org/10.1007/s00415-023-11671-9.
Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.
Cortese R. et al. (2023) ‘Clinical and MRI measures to identify non-acute MOG-antibody disease in adults’, Brain, 146(6), pp. 2489–2501. Available at: https://doi.org/10.1093/brain/awac480.
Dittrich, Tolga D et al. (2023) ‘Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications – the PLEURA study’, European Stroke Journal, 8(2), pp. 549–556. Available at: https://doi.org/10.1177/23969873231151488.
Dittrich, Tolga D et al. (2023) ‘Apical pulmonary lesions suspected of malignancy visible on neck CT angiography performed for acute stroke: Prevalence, treatment, and clinical implications – the PLEURA study’, European Stroke Journal, 8(2), pp. 549–556. Available at: https://doi.org/10.1177/23969873231151488.
Traenka, Christopher et al. (2023) ‘Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration’, Journal of Stroke, 25(2), pp. 272–281. Available at: https://doi.org/10.5853/jos.2022.03370.
Traenka, Christopher et al. (2023) ‘Recanalization Therapies for Large Vessel Occlusion Due to Cervical Artery Dissection: A Cohort Study of the EVA-TRISP Collaboration’, Journal of Stroke, 25(2), pp. 272–281. Available at: https://doi.org/10.5853/jos.2022.03370.
Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29(6), pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.
Tsagkas, Charidimos et al. (2023) ‘Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis’, Multiple Sclerosis Journal, 29(6), pp. 702–718. Available at: https://doi.org/10.1177/13524585221139152.
Pfeuffer S. et al. (2023) ‘Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab’, Neurology: Neuroimmunology and NeuroInflammation, 10(3). Available at: https://doi.org/10.1212/NXI.0000000000200104.
Pfeuffer S. et al. (2023) ‘Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab’, Neurology: Neuroimmunology and NeuroInflammation, 10(3). Available at: https://doi.org/10.1212/NXI.0000000000200104.
Agosti, Reto et al. (2023) ‘Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study’, Pain and Therapy, 12(2), pp. 575–591. Available at: https://doi.org/10.1007/s40122-023-00484-3.
Agosti, Reto et al. (2023) ‘Prevalence and Burden of Migraine in Switzerland: Cross-Sectional Study in ten Specialised Headache Centres from the BECOME Study’, Pain and Therapy, 12(2), pp. 575–591. Available at: https://doi.org/10.1007/s40122-023-00484-3.
Cagol A et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis’, Journal of Neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.
Cagol A et al. (2023) ‘Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis’, Journal of Neurology, 270(4), pp. 2139–2148. Available at: https://doi.org/10.1007/s00415-022-11535-8.
Diouf I. et al. (2023) ‘Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis’, European Journal of Neurology, 30(4), pp. 1014–1024. Available at: https://doi.org/10.1111/ene.15706.
Diouf I. et al. (2023) ‘Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis’, European Journal of Neurology, 30(4), pp. 1014–1024. Available at: https://doi.org/10.1111/ene.15706.
Vrenken H. et al. (2023) ‘Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a’, Journal of Neurology, 270(4), pp. 2271–2282. Available at: https://doi.org/10.1007/s00415-022-11554-5.
Vrenken H. et al. (2023) ‘Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a’, Journal of Neurology, 270(4), pp. 2271–2282. Available at: https://doi.org/10.1007/s00415-022-11554-5.